Product Outlicensing/Co-development Opportunities

GFT505: Diabetic Dyslipidemia (Phase II)
Genfit’s most advanced molecule, GFT505, is a new generation drug candidate developed in-house which targets the treatment of diabetic and dyslipidemic patients. Through a simultaneous action on different types and/or subtypes of receptors, GFT505 and its back-up are pluripotent molecules with beneficial effects on several risk factors associated with prediabetes and diabetes, such as the lipid triad (HDL-cholesterol, triglycerides and LDL-cholesterol), inflammation, and insulin resistance. GFT505 is currently in phase IIa clinical studies and Genfit seeks to identify a partner with global reach as these studies conclude in late 2009.
Click here to learn more about GFT505.

Biomarkers (Atherosclerosis, Pancreas Deficiency, and Neurodegenerative Disorders)
Genfit has successfully developed a non-invasive non-imaging biomarker technology to monitor atherosclerotic plaque. This technology can match the signature of atherosclerotic plaque size and composition to circulatory markers in the blood.  Additionally, Genfit has applied this technology in determination of circulatory markers for prediabetes and neurodegenerative disorders.  Genfit is in the position to apply this technology platform to a partner's drug development program in order to provide a decision-making tool for compound profiling in both preclinical and clinical settings.  Genfit is also interested in exploring opportunities with diagnostic companies to further develop and optimize this technology for atherosclerosis, prediabetes and neurodegenerative disorders.

Neurodegenerative Disorders
Genfit has selected several Nuclear Receptors (NRs) that may represent next-generation therapeutic targets for neurodegenerative disorders such as Alzheimer’s disease. NRs are transcription factors that can be modulated by small molecules to act on several physiological and pathophysiological pathways. Pharmacological drugs modulating NR function have already shown efficacy in the treatment of a variety of human diseases, but NRs are a largely unexploited therapeutic field in the central nervous system (CNS). Genfit has early-stage programs on 2 NRs of relevance in neurodegenerative disorders. Genfit’s 3rd NR program is more advanced, as a lead compound with appropriate CNS pharmacokinetic features has been identified.

Gene X: Obesity and Diabetes
Genfit has identified “Gene X” as a potential target against obesity and diabetes that encodes a “druggable” enzyme preferentially expressed in human visceral adipose tissue. Genfit’s in vitro and in vivo data suggest that Gene X contributes to visceral adiposity and is implicated in lipid storage and fat accumulation.  Gene X-deficient mice are resistant to diet-induced obesity (DIO) and show reduced adipocyte size and decreased macrophage infiltration and adipose tissue inflammation. Moreover, Gene X-deficient mice maintain glucose tolerance after high-fat diet feeding, thus suggesting a role for Gene X in the development of insulin resistance. Genfit has developed a primary assay to identify novel compounds acting on Gene X, as well as secondary profiling assays and in vivo models to further characterize compounds. With a comprehensive package based on this innovative concept, Genfit is currently seeking a partner to accelerate the drug discovery process for this exciting target.

Technology Platforms and Resources
Genfit also offers many services to assist in profiling, genomics, pharmacology, screening, chemistry, proteomics, and bioinformatics. Genfit has a brand new state-of-the-art animal facility, and the ability to conduct preclinical studies in up to 5 species. Animal models include, but are not limited to, diabetes, obesity, dyslipidemia, and inflammation.  In addition, Genfit has several different types of transgenic and KO models. Genfit's in vitro profiling services include gene expression studies and a variety of functional assays in primary and established cell lines, siRNA technology, and high-throughput Affymetrix studies.

To learn more about our different early stage programme opportunities, please contact  our Business Development Team.